FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT
Enzolytics, Inc. Announces Groundbreaking Research
September 18, 2024
Enzolytics, Inc. (OTC PINK:ENZC) has made a significant stride in the field of immunology with its latest collaborative effort. The Department of Immunology at the Institute of Microbiology, Bulgarian Academy of Sciences, led by Professor Tchorbanov PhD and Penka Petrova PHD, DSc, has released its first report as part of a newly formed partnership with Enzolytics. This groundbreaking research aims to investigate the effects of ENZC’s experimental cancer treatment, Irreversible Pepsin Fraction (“IPF”), on vital organs and the immune system.
The study, which was sponsored by Rosetta, LLC, focused on evaluating any potential pathological changes in the Kidney, Liver, Lymph Nodes, and Spleen following the administration of IPF. Additionally, the researchers assessed the activation of the immune system, observed for any side effects, and monitored the survival rates of the animal subjects involved in the study, which utilized a mouse model on the Balb/c inbred mouse line under specific pathogen-free sterile conditions.
This collaboration marks a significant milestone for Enzolytics, highlighting the company’s dedication to advancing the field of immunotherapy and bringing new, innovative treatments to the forefront of cancer research. By working closely with esteemed institutions and leading experts in the field, Enzolytics is paving the way for the development of potential life-saving therapies.
Impact on Individuals
As a result of this collaborative research effort, individuals may benefit from the development of more effective and targeted cancer treatments. The findings from this study could potentially lead to the emergence of new therapies that have fewer side effects and improved survival rates for cancer patients.
Global Implications
The research conducted by Enzolytics and its partners has the potential to have a significant impact on the world of cancer treatment. By advancing our understanding of how IPF affects the immune system and vital organs, this study could pave the way for the development of new therapies that have the potential to revolutionize the way we approach cancer treatment on a global scale.
Conclusion
The collaboration between Enzolytics and the Department of Immunology at the Institute of Microbiology, Bulgarian Academy of Sciences represents a major step forward in cancer research and immunotherapy. By conducting innovative studies and forging partnerships with leading experts in the field, Enzolytics is positioning itself at the forefront of cutting-edge cancer treatments that have the potential to benefit individuals worldwide and transform the landscape of cancer care.
